{"id":72584,"date":"2026-03-13T05:04:37","date_gmt":"2026-03-13T05:04:37","guid":{"rendered":"https:\/\/www.stocktargetadvisor.com\/blog\/?p=72584"},"modified":"2026-03-13T05:04:37","modified_gmt":"2026-03-13T05:04:37","slug":"latest-us-analyst-ratings-march-12th-2026","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/","title":{"rendered":"Latest US Analyst Ratings: March 12th, 2026"},"content":{"rendered":"

Analyst Ratings (USA)<\/strong><\/a><\/h2>\n

Today\u2019s 408 U.S. analyst ratings show a mix of cautious optimism and selective buying opportunities across sectors. Major tech and energy names like Apple, NVIDIA, Chevron, and ConocoPhillips continue to see strong buy or overweight endorsements with raised price targets, reflecting confidence in growth and energy demand. Financials and airlines have mixed views, with several Hold or Neutral ratings amid economic uncertainty and margin pressures. Healthcare and biotech updates are active, with new coverage initiations and price target adjustments signaling both high potential and volatility. Overall, analysts are balancing growth prospects with caution, favoring established leaders while trimming targets on more cyclical or overextended names.<\/p>\n

Alcoa \u2013 AA:<\/strong> UBS Group raised the price target to $70 from $48 with a Neutral rating; Wells Fargo & Company set a $68 target.<\/p>\n

American Airlines Group \u2013 AAL:<\/strong> Jefferies Financial Group lowered the target to $12 from $15 and maintained a Hold rating.<\/p>\n

Ascentage Pharma Group International \u2013 AAPG:<\/strong> BTIG Research initiated coverage with a Buy rating and $48 price target.<\/p>\n

Apple \u2013 AAPL:<\/strong> KeyCorp reiterated a Sector Weight rating.<\/p>\n

AbbVie \u2013 ABBV:<\/strong> Guggenheim reiterated a Buy rating.<\/p>\n

Acco Brands \u2013 ACCO:<\/strong> Barrington Research cut the price target to $5 from $6 with an Outperform rating.<\/p>\n

ProFrac \u2013 ACDC:<\/strong> UBS Group reiterated a Positive rating.<\/p>\n

Acacia Research \u2013 ACTG:<\/strong> Craig Hallum raised the price target to $6 from $5 and maintained a Buy rating.<\/p>\n

American Electric Power \u2013 AEP:<\/strong> JPMorgan Chase & Co. raised the target to $139 from $125 with a Neutral rating.<\/p>\n

Grupo Aeromexico \u2013 AERO:<\/strong> JPMorgan Chase & Co. lowered the price target to $28 from $28.50 while maintaining an Overweight rating.<\/p>\n

Atlas Energy Solutions \u2013 AESI:<\/strong> Barclays raised the price target to $11 from $8 with an Underweight rating.<\/p>\n

American Healthcare REIT \u2013 AHR:<\/strong> Truist Financial set a $57 price target.<\/p>\n

Akamai Technologies \u2013 AKAM:<\/strong> Raymond James Financial set a $120 price target.<\/p>\n

AMETEK \u2013 AME:<\/strong> Morgan Stanley raised the target to $235 from $215 with an Equal Weight rating.<\/p>\n

Aemetis \u2013 AMTX:<\/strong> Loop Capital set a $1.75 price target.<\/p>\n

AnaptysBio \u2013 ANAB:<\/strong> Wedbush raised the price target to $75 from $60 with an Outperform rating.<\/p>\n

Arista Networks \u2013 ANET:<\/strong> TD Cowen initiated coverage with a Buy rating and $170 target.<\/p>\n

APA Corp \u2013 APA:<\/strong> Piper Sandler raised the price target to $37 from $30 with a Neutral rating.<\/p>\n

Aptiv \u2013 APTV:<\/strong> UBS Group upgraded the stock to Buy from Neutral and raised the target to $97 from $89.<\/p>\n

Ardelyx \u2013 ARDX:<\/strong> Leerink Partners reiterated an Outperform rating; Williams Trading set a $17 price target.<\/p>\n

AdvanSix \u2013 ASIX:<\/strong> Loop Capital set a $25 price target.<\/p>\n

Aveanna Healthcare \u2013 AVAH:<\/strong> Truist Financial set a $10 price target.<\/p>\n

AeroVironment \u2013 AVAV:<\/strong> Canaccord Genuity Group cut target to $300 from $330; Jefferies Financial Group lowered target to $305 from $390; BTIG Research lowered target to $330 from $415, all maintaining Buy ratings.<\/p>\n

ArriVent BioPharma \u2013 AVBP:<\/strong> BTIG Research initiated coverage with a Buy rating and $42 target.<\/p>\n

Anteris Technologies Global \u2013 AVR:<\/strong> Cantor Fitzgerald initiated coverage with an Overweight rating and $15 target.<\/p>\n

BridgeBio Pharma \u2013 BBIO:<\/strong> Leerink Partners reiterated an Outperform rating with a $98 price target.<\/p>\n

Black Hills \u2013 BKH:<\/strong> Siebert Williams Shank upgraded the stock to Buy from Hold and raised the target to $82 from $79.<\/p>\n

Bumble \u2013 BMBL:<\/strong> JPMorgan upgraded to Neutral; Citigroup raised target to $3.90; multiple brokers adjusted targets amid mixed outlooks.<\/p>\n

BioMarin Pharmaceutical \u2013 BMRN:<\/strong> Jefferies Financial Group reiterated a Buy rating with a $103 target.<\/p>\n

Box \u2013 BOX:<\/strong> Morgan Stanley lowered the price target to $33 from $38 with an Equal Weight rating.<\/p>\n

BP \u2013 BP:<\/strong> Piper Sandler raised the price target to $47 from $44 with a Neutral rating.<\/p>\n

Braze \u2013 BRZE:<\/strong> JPMorgan Chase & Co. lowered the price target to $32 from $45 with an Overweight rating.<\/p>\n

biote \u2013 BTMD:<\/strong> B. Riley lowered target to $2; TD Cowen to $2.50; National Bank Financial set a $2.50 target.<\/p>\n

Peabody Energy \u2013 BTU:<\/strong> UBS Group raised the price target to $34.50 from $34 with a Neutral rating.<\/p>\n

BrainsWay \u2013 BWAY:<\/strong> HC Wainwright cut the price target to $15 from $30 with a Buy rating.<\/p>\n

BWX Technologies \u2013 BWXT:<\/strong> TD Cowen and TD Securities initiated coverage with Buy ratings and $230 price targets.<\/p>\n

Conagra Brands \u2013 CAG:<\/strong> Wells Fargo & Company downgraded rating to Underweight from Equal Weight and lowered target to $15 from $20.<\/p>\n

Pathward Financial \u2013 CASH:<\/strong> Piper Sandler initiated coverage with an Overweight rating and $107 target.<\/p>\n

Celanese \u2013 CE:<\/strong> Citigroup raised the price target to $81 from $75 and maintained a Buy rating.<\/p>\n

Century Aluminum \u2013 CENX:<\/strong> Wells Fargo & Company raised the price target to $69 from $61 with an Overweight rating.<\/p>\n

Cigna Group \u2013 CI:<\/strong> Sanford C. Bernstein upgraded to Outperform from Market Perform and raised target to $358 from $307.<\/p>\n

Canadian Natural Resources \u2013 CNQ:<\/strong> The Goldman Sachs Group raised price target to $49 from $37 with a Buy rating.<\/p>\n

ConocoPhillips \u2013 COP:<\/strong> Piper Sandler raised the price target to $154 from $111 with an Overweight rating.<\/p>\n

Campbell\u2019s \u2013 CPB:<\/strong> Multiple brokers cut targets; several downgraded stock amid weaker outlooks.<\/p>\n

Crocs \u2013 CROX:<\/strong> Williams Trading upgraded the stock to Hold from Sell with an $84 target.<\/p>\n

CSX \u2013 CSX:<\/strong> Bank of America lowered the price target to $46 from $48 while maintaining a Buy rating.<\/p>\n

Coterra Energy \u2013 CTRA:<\/strong> Piper Sandler raised the price target to $47 from $41 with an Overweight rating.<\/p>\n

CVS Health \u2013 CVS:<\/strong> Sanford C. Bernstein upgraded to Outperform from Market Perform and raised target to $94 from $91.<\/p>\n

Chevron \u2013 CVX:<\/strong> Piper Sandler raised the price target to $242 from $179 with an Overweight rating.<\/p>\n

Delta Air Lines \u2013 DAL:<\/strong> Jefferies Financial Group lowered target to $72 from $84 while maintaining a Buy rating.<\/p>\n

Dollar General \u2013 DG:<\/strong> Multiple brokerages reiterated ratings from Neutral to Buy, with new targets around $139.<\/p>\n

Ginkgo Bioworks \u2013 DNA:<\/strong> BTIG Research cut the price target to $5 from $9 with a Sell rating.<\/p>\n

Devon Energy \u2013 DVN:<\/strong> Piper Sandler raised the price target to $67 from $59 with an Overweight rating.<\/p>\n

Diamondback Energy \u2013 FANG:<\/strong> Piper Sandler raised the price target to $248 from $215 with an Overweight rating.<\/p>\n

Franco-Nevada \u2013 FNV:<\/strong> HC Wainwright raised the price target to $305 from $285 with a Buy rating.<\/p>\n

Corning \u2013 GLW:<\/strong> Bank of America raised the price target to $144 from $120 with a Buy rating.<\/p>\n

General Mills \u2013 GIS:<\/strong> Wells Fargo & Company downgraded the stock to Underweight from Equal Weight and cut target to $35 from $45.<\/p>\n

Honeywell \u2013 HON:<\/strong> Morgan Stanley raised the price target to $245 from $235 with an Equal Weight rating.<\/p>\n

Jabil \u2013 JBL:<\/strong> JPMorgan Chase & Co. raised the price target to $300 from $270 with an Overweight rating; Robert W. Baird initiated coverage with an Outperform rating and $275 target.<\/p>\n

Jefferies Financial Group \u2013 JEF:<\/strong> UBS Group lowered target to $59 from $76 with a Buy rating; Goldman Sachs Group cut target to $54 from $61 and maintained Buy rating.<\/p>\n

Joby Aviation \u2013 JOBY:<\/strong> HC Wainwright reiterated a Buy rating with an $18 target.<\/p>\n

Kodiak AI \u2013 KDK:<\/strong> TD Cowen lowered the price target to $13 from $14 with a Buy rating.<\/p>\n

Kinross Gold \u2013 KGC:<\/strong> Royal Bank of Canada upgraded to Outperform from Sector Perform and raised target to $45 from $36.<\/p>\n

Kraft Heinz \u2013 KHC:<\/strong> Wells Fargo & Company lowered the target to $23 from $25 and maintained an Equal Weight rating.<\/p>\n

Kamada \u2013 KMDA:<\/strong> Benchmark reiterated a Buy rating.<\/p>\n

Kohl\u2019s \u2013 KSS:<\/strong> Bank of America cut the target to $15 from $18 with an Underperform rating.<\/p>\n

Lazard \u2013 LAZ:<\/strong> UBS Group lowered the price target to $48 from $59 with a Neutral rating; Goldman Sachs Group reduced target to $46 from $53 and maintained a Sell rating.<\/p>\n

Lear \u2013 LEA:<\/strong> Royal Bank of Canada initiated coverage with a Sector Perform rating and $135 target.<\/p>\n

Levi Strauss & Co. \u2013 LEVI:<\/strong> UBS Group reiterated a Buy rating.<\/p>\n

LifeMD \u2013 LFMD:<\/strong> Loop Capital set a $10 price target.<\/p>\n

Lumentum \u2013 LITE:<\/strong> TD Cowen initiated coverage with a Hold rating and $675 target.<\/p>\n

Liquidia \u2013 LQDA:<\/strong> Oppenheimer raised target to $19 from $16 with an Underperform rating.<\/p>\n

Life Time Group \u2013 LTH:<\/strong> KeyCorp initiated coverage with an Overweight rating and $40 target; UBS Group reiterated a Buy rating with a $43 price target.<\/p>\n

Lululemon Athletica \u2013 LULU:<\/strong> BTIG Research lowered target to $250 from $303 while maintaining a Buy rating.<\/p>\n

Southwest Airlines \u2013 LUV:<\/strong> Jefferies Financial Group reduced target to $41 from $48 with a Hold rating.<\/p>\n

Lexicon Pharmaceuticals \u2013 LXRX:<\/strong> HC Wainwright set a $6 price target.<\/p>\n

LSB Industries \u2013 LXU:<\/strong> Jefferies Financial Group raised target to $15 from $11 with a Hold rating.<\/p>\n

LyondellBasell Industries \u2013 LYB:<\/strong> Citigroup upgraded to Buy from Neutral and raised target to $76 from $49; Wells Fargo & Company set a $76 price target.<\/p>\n

Live Nation Entertainment \u2013 LYV:<\/strong> Goldman Sachs Group raised target to $190 from $175 with a Buy rating.<\/p>\n

MBX Biosciences \u2013 MBX:<\/strong> TD Cowen reiterated a Buy rating.<\/p>\n

Moelis & Company \u2013 MC:<\/strong> UBS Group lowered target to $59 from $74 with a Neutral rating; Goldman Sachs Group reduced target to $70 from $80 with a Neutral rating.<\/p>\n

MercadoLibre \u2013 MELI:<\/strong> JPMorgan Chase & Co. downgraded stock to Neutral from Overweight and cut target to $2,100 from $2,650.<\/p>\n

Magnolia Oil & Gas \u2013 MGY:<\/strong> Piper Sandler raised target to $31 from $28 with a Neutral rating.<\/p>\n

Martin Midstream Partners \u2013 MMLP:<\/strong> Stifel Nicolaus lowered target to $3 from $4 with a Hold rating.<\/p>\n

Molina Healthcare \u2013 MOH:<\/strong> Mizuho cut target to $180 from $220 with an Outperform rating; UBS Group raised target to $151 from $145 with a Neutral rating.<\/p>\n

Marathon Petroleum \u2013 MPC:<\/strong> Goldman Sachs Group raised target to $239 from $211 with a Buy rating.<\/p>\n

Merck & Co. \u2013 MRK:<\/strong> Wells Fargo & Company raised price target to $150 from $135 with an Overweight rating.<\/p>\n

MGIC Investment \u2013 MTG:<\/strong> UBS Group lowered target to $28 from $29.50 with a Neutral rating.<\/p>\n

Vail Resorts \u2013 MTN:<\/strong> Morgan Stanley reduced target to $147 from $151 with an Equal Weight rating.<\/p>\n

Micron Technology \u2013 MU:<\/strong> Wells Fargo & Company raised price target to $470 from $410 with an Overweight rating.<\/p>\n

Murphy Oil \u2013 MUR:<\/strong> Piper Sandler upgraded stock to Overweight from Neutral and raised target to $41 from $33.<\/p>\n

Nature\u2019s Sunshine Products \u2013 NATR:<\/strong> DA Davidson raised target to $33 from $23 with a Buy rating.<\/p>\n

Neurocrine Biosciences \u2013 NBIX:<\/strong> JPMorgan Chase & Co. raised target slightly to $177 from $176 with an Overweight rating.<\/p>\n

Nanobiotix \u2013 NBTX:<\/strong> TD Cowen reiterated a Buy rating.<\/p>\n

Minerva Neurosciences \u2013 NERV:<\/strong> HC Wainwright reiterated a Neutral rating and raised target to $7 from $4.<\/p>\n

National Health Investors \u2013 NHI:<\/strong> Truist Financial raised target to $92 from $85 with a Buy rating.<\/p>\n

Nike \u2013 NKE:<\/strong> Jefferies Financial Group reiterated a Buy rating.<\/p>\n

North American Construction Group \u2013 NOA:<\/strong> BMO Capital Markets downgraded the stock to Market Perform from Outperform.<\/p>\n

Northern Oil and Gas \u2013 NOG:<\/strong> Piper Sandler raised target to $32 from $27 with a Neutral rating.<\/p>\n

Nutrien \u2013 NTR:<\/strong> Jefferies Financial Group upgraded stock to Buy from Hold and raised target to $96 from $74.<\/p>\n

Netskope \u2013 NTSK:<\/strong> Morgan Stanley, BMO Capital Markets, Royal Bank of Canada, and JPMorgan Chase & Co. lowered targets while maintaining Buy\/Outperform ratings.<\/p>\n

Novavax \u2013 NVAX:<\/strong> Jefferies Financial Group reiterated a Buy rating.<\/p>\n

NVIDIA \u2013 NVDA:<\/strong> William Blair set target at $300; Cantor Fitzgerald reiterated Overweight rating with $300 target<\/p>\n

Navitas Semiconductor \u2013 NVTS:<\/strong> Rosenblatt Securities reiterated a Neutral rating with a $7 target.<\/p>\n

Orchestra BioMed \u2013 OBIO:<\/strong> Chardan Capital reiterated a Buy rating with a $20 target.<\/p>\n

Olin \u2013 OLN:<\/strong> Citigroup raised target to $26 from $21 with a Neutral rating.<\/p>\n

Omada Health \u2013 OMDA:<\/strong> JPMorgan Chase & Co. lowered target to $26 from $32 with an Overweight rating.<\/p>\n

Oracle \u2013 ORCL:<\/strong> Citigroup raised target to $320 from $310 with a Buy rating.<\/p>\n

Occidental Petroleum \u2013 OXY:<\/strong> Wells Fargo & Company upgraded from Underweight to Overweight, target $69 from $47; Piper Sandler upgraded from Neutral to Overweight, target $66 from $54.<\/p>\n

Par Pacific \u2013 PARR:<\/strong> Goldman Sachs Group raised target to $53 from $44 with a Neutral rating.<\/p>\n

UiPath \u2013 PATH:<\/strong> Morgan Stanley lowered target to $17 from $19 with Equal Weight rating.<\/p>\n

UiPath \u2013 PATH:<\/strong> Mizuho lowered target to $12 from $15 with Neutral rating.<\/p>\n

UiPath \u2013 PATH: Wells Fargo & Company lowered target to $13 from $14 with Equal Weight rating.<\/p>\n

UiPath \u2013 PATH:<\/strong> Canaccord Genuity Group lowered target to $15 from $19 with Buy rating.<\/p>\n

UiPath \u2013 PATH:<\/strong> Truist Financial lowered target to $12 from $17 with Hold rating.<\/p>\n

UiPath \u2013 PATH:<\/strong> TD Cowen lowered target to $13 from $16 with Hold rating.<\/p>\n

UiPath \u2013 PATH:<\/strong> DA Davidson lowered target to $13 from $15 with Neutral rating.<\/p>\n

UiPath \u2013 PATH:<\/strong> UBS Group lowered target to $13 from $17 with Neutral rating.<\/p>\n

UiPath \u2013 PATH:<\/strong> Needham & Company LLC upgraded rating from Hold to Buy with $15 target.<\/p>\n

UiPath \u2013 PATH:<\/strong> Bank of America lowered target to $12 from $14 with Underperform rating.<\/p>\n

UiPath \u2013 PATH:<\/strong> William Blair reiterated Market Perform rating.<\/p>\n

PBF Energy \u2013 PBF:<\/strong> Goldman Sachs Group raised target to $41 from $33 with a Neutral rating.<\/p>\n

Public Service Enterprise Group \u2013 PEG:<\/strong> JPMorgan Chase & Co. raised target to $90 from $85 with a Neutral rating.<\/p>\n

PENN Entertainment \u2013 PENN:<\/strong> Mizuho raised target to $22 from $19 with an Outperform rating.<\/p>\n

PepsiCo \u2013 PEP:<\/strong> Piper Sandler raised target to $181 from $172 with an Overweight rating.<\/p>\n

Pharming Group \u2013 PHAR:<\/strong> HC Wainwright set a $37 target with a Buy rating.<\/p>\n

PulteGroup \u2013 PHM:<\/strong> UBS Group reiterated a Buy rating.<\/p>\n

Piper Sandler Companies \u2013 PIPR:<\/strong> Goldman Sachs Group lowered target to $392 from $461 with a Buy rating.<\/p>\n

PJT Partners \u2013 PJT:<\/strong> UBS Group lowered target to $151 from $180 with a Neutral rating.<\/p>\n

Planet Fitness \u2013 PLNT:<\/strong> KeyCorp initiated coverage with Overweight rating and $100 target.<\/p>\n

Pliant Therapeutics \u2013 PLRX:<\/strong> Piper Sandler lowered target to $3 from $4 with an Overweight rating.<\/p>\n

Permian Resources \u2013 PR:<\/strong> Piper Sandler raised target to $27 from $24 with an Overweight rating.<\/p>\n

Prime Medicine \u2013 PRME:<\/strong> Oppenheimer initiated coverage with an Outperform rating and $11 target.<\/p>\n

ProQR Therapeutics \u2013 PRQR:<\/strong> Oppenheimer initiated coverage with an Outperform rating and $9 target.<\/p>\n

Phillips 66 \u2013 PSX:<\/strong> Goldman Sachs Group raised target to $186 from $168 with a Neutral rating.<\/p>\n

Perella Weinberg Partners \u2013 PWP:<\/strong> Goldman Sachs Group lowered target to $18.50 from $21.50 with a Sell rating.<\/p>\n

Ultragenyx Pharmaceutical \u2013 RARE:<\/strong> JPMorgan Chase & Co. lowered target to $74 from $120 with an Overweight rating.<\/p>\n

Radian Group \u2013 RDN:<\/strong> UBS Group lowered target to $39 from $41 with a Neutral rating.<\/p>\n

Regions Financial \u2013 RF:<\/strong> Brean Capital initiated coverage with a Neutral rating<\/p>\n

Rivian Automotive \u2013 RIVN:<\/strong> Benchmark reiterated a Buy rating; Leerink Partners reiterated an Outperform rating.<\/p>\n

Range Resources \u2013 RRC:<\/strong> Piper Sandler raised target to $42 from $41 with a Neutral rating.<\/p>\n

Rentokil Initial \u2013 RTO:<\/strong> UBS Group upgraded rating from Neutral to Buy.<\/p>\n

Ryanair \u2013 RYAAY:<\/strong> Evercore upgraded rating from In-Line to Outperform with $80 target.<\/p>\n

Rhythm Pharmaceuticals \u2013 RYTM:<\/strong> Wells Fargo & Company raised target to $143 from $136 with Overweight; Telsey Advisory Group set $143 target.<\/p>\n

Smith Douglas Homes \u2013 SDHC:<\/strong> Wells Fargo & Company lowered target to $14 from $18 with Equal Weight rating.<\/p>\n

Vivid Seats \u2013 SEAT:<\/strong> Bank of America reiterated an Underperform rating with $5.65 target.<\/p>\n

Stitch Fix \u2013 SFIX:<\/strong> Telsey Advisory Group lowered target to $5 from $6 with a Market Perform rating.<\/p>\n

Shell \u2013 SHEL:<\/strong> Piper Sandler raised target to $106 from $89 with Overweight rating.<\/p>\n

Shopify \u2013 SHOP:<\/strong> Piper Sandler initiated coverage with Overweight rating and $165 target.<\/p>\n

SLB \u2013 SLB:<\/strong> Sanford C. Bernstein raised target to $56.10 from $52.30 with an Outperform rating.<\/p>\n

Solid Biosciences \u2013 SLDB:<\/strong> Chardan Capital reiterated a Buy rating with a $15 target.<\/p>\n

Sarepta Therapeutics \u2013 SRPT:<\/strong> Mizuho set a $31 target.<\/p>\n

Silver Standard Resources \u2013 SSRM:<\/strong> CIBC upgraded rating from Neutral to Sector Outperform with $48 target.<\/p>\n

SURO Capital \u2013 SSSS:<\/strong> Citizens Jmp raised target to $13 from $11 with a Market Outperform rating.<\/p>\n

Suncor Energy \u2013 SU:<\/strong> Goldman Sachs Group raised target to $62 from $55 with a Buy rating.<\/p>\n

TAT Technologies \u2013 TATT:<\/strong> Benchmark raised target to $66 from $58 with a Buy rating.<\/p>\n

Bancorp \u2013 TBBK:<\/strong> Piper Sandler initiated coverage with Overweight rating and $66 target.<\/p>\n

Atlassian \u2013 TEAM:<\/strong> Mizuho lowered target to $185 from $205 with Outperform; Wolfe Research reiterated Outperform with $100 target.<\/p>\n

Tenet Healthcare \u2013 THC:<\/strong> Mizuho raised target to $265 from $235 with Outperform; Guggenheim raised target to $283 from $271 with Buy.<\/p>\n

Tenaya Therapeutics \u2013 TNYA:<\/strong> Chardan Capital reiterated Buy with $8 target; William Blair reiterated Outperform; Leerink Partners reiterated Outperform with $2 target.<\/p>\n

Tapestry \u2013 TPR:<\/strong> Argus set a $165 target.<\/p>\n

Trustmark \u2013 TRMK:<\/strong> Brean Capital initiated coverage with Buy rating.<\/p>\n

TPG RE Finance Trust \u2013 TRTX:<\/strong> Citizens Jmp upgraded rating from Market Perform to Outperform with $10 target; Citigroup upgraded from Market Perform to Outperform.<\/p>\n

Travelers Companies \u2013 TRV:<\/strong> Brean Capital initiated coverage with Neutral rating.<\/p>\n

ServiceTitan \u2013 TTAN:<\/strong> BTIG Research lowered target to $105 from $130 with Buy rating.<\/p>\n

TechTarget \u2013 TTGT:<\/strong> Needham & Company reiterated Buy rating; Lake Street Capital lowered target to $8 from $10 with Buy.<\/p>\n

United Airlines \u2013 UAL:<\/strong> Jefferies Financial Group lowered target to $125 from $148 with Buy rating.<\/p>\n

UniFirst \u2013 UNF:<\/strong> Barclays raised target to $280 from $250 with Equal Weight rating.<\/p>\n

United Natural Foods \u2013 UNFI:<\/strong> Deutsche Bank raised target to $46 from $40 with Hold rating.<\/p>\n

United Therapeutics \u2013 UTHR:<\/strong> Cantor Fitzgerald raised target to $625 from $525 with Overweight rating.<\/p>\n

Telefonica Brasil \u2013 VIV:<\/strong> Barclays reiterated Equal Weight rating with $16 target.<\/p>\n

Valero Energy \u2013 VLO:<\/strong> Goldman Sachs Group raised target to $237 from $203 with Buy rating.<\/p>\n

Viper Energy \u2013 VNOM:<\/strong> Piper Sandler raised target to $68 from $64 with Overweight rating.<\/p>\n

VSE \u2013 VSEC:<\/strong> William Blair reiterated an Outperform rating.<\/p>\n

Verastem \u2013 VSTM:<\/strong> BTIG Research initiated coverage with Buy rating and $19 target.<\/p>\n

vTv Therapeutics \u2013 VTVT:<\/strong> Evercore initiated coverage with Outperform rating and $44 target.<\/p>\n

Verizon Communications \u2013 VZ:<\/strong> Raymond James Financial reiterated Outperform rating with $56 target.<\/p>\n

Waystar \u2013 WAY:<\/strong> Deutsche Bank lowered target to $37 from $42 with Buy rating.<\/p>\n

Workday \u2013 WDAY:<\/strong> Loop Capital set a $210 target.<\/p>\n

Western Midstream Partners \u2013 WES:<\/strong> JPMorgan Chase & Co. lowered target to $43 from $44 with Neutral rating.<\/p>\n

Wix.com \u2013 WIX:<\/strong> Piper Sandler initiated coverage with Neutral rating.<\/p>\n

Westlake \u2013 WLK:<\/strong> Citigroup raised target to $130 from $124 with Buy rating.<\/p>\n

Wealthfront \u2013 WLTH:<\/strong> Keefe, Bruyette & Woods reiterated Market Perform; Wells Fargo lowered target to $12 from $12.50 with Overweight; JPMorgan lowered target to $10 from $16 with Overweight; Goldman Sachs lowered target to $10.50 from $12 with Neutral rating.<\/p>\n

Petco Health and Wellness \u2013 WOOF:<\/strong> Jefferies Financial Group upgraded rating from Hold to Buy with $5 target.<\/p>\n

WesBanco \u2013 WSBC:<\/strong> Raymond James Financial reiterated Strong-Buy rating with $41 target.<\/p>\n

Williams-Sonoma \u2013 WSM:<\/strong> Telsey Advisory Group reiterated Outperform rating with $220 target<\/p>\n

Woodward \u2013 WWD:<\/strong> UBS Group reiterated Buy rating.<\/p>\n

Xcel Energy \u2013 XEL:<\/strong> Argus set an $86 target.<\/p>\n

Exxon Mobil \u2013 XOM:<\/strong> Piper Sandler raised target to $186 from $145 with Overweight rating.<\/p>\n

Xponential Fitness \u2013 XPOF:<\/strong> KeyCorp initiated coverage with Sector Weight rating.<\/p>\n

Full Truck Alliance \u2013 YMM:<\/strong> Morgan Stanley reiterated Overweight rating.<\/p>\n

JOYY \u2013 YY:<\/strong> Benchmark reiterated Buy rating.<\/p>\n

Zions Bancorporation, N.A. \u2013 ZION:<\/strong> Brean Capital initiated coverage with Neutral rating.<\/p>\n","protected":false},"excerpt":{"rendered":"

Analyst Ratings (USA) Today\u2019s 408 U.S. analyst ratings show a mix of cautious optimism and selective buying opportunities across sectors. Major tech and energy names…<\/p>\n","protected":false},"author":3,"featured_media":71566,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-72584","post","type-post","status-publish","format-image","has-post-thumbnail","hentry","category-blog","post_format-post-format-image"],"acf":[],"yoast_head":"\nLatest US Analyst Ratings: March 12th, 2026 | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Latest US Analyst Ratings: March 12th, 2026\" \/>\n<meta property=\"og:description\" content=\"Analyst Ratings (USA) Today\u2019s 408 U.S. analyst ratings show a mix of cautious optimism and selective buying opportunities across sectors. Major tech and energy names...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-13T05:04:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2026\/02\/Analyst-Ratings-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"Latest US Analyst Ratings: March 12th, 2026\",\"datePublished\":\"2026-03-13T05:04:37+00:00\",\"dateModified\":\"2026-03-13T05:04:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/\"},\"wordCount\":2778,\"commentCount\":938,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News & Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/\",\"name\":\"Latest US Analyst Ratings: March 12th, 2026 | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2026-03-13T05:04:37+00:00\",\"dateModified\":\"2026-03-13T05:04:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Latest US Analyst Ratings: March 12th, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Latest US Analyst Ratings: March 12th, 2026 | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/","og_locale":"en_US","og_type":"article","og_title":"Latest US Analyst Ratings: March 12th, 2026","og_description":"Analyst Ratings (USA) Today\u2019s 408 U.S. analyst ratings show a mix of cautious optimism and selective buying opportunities across sectors. Major tech and energy names...","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2026-03-13T05:04:37+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2026\/02\/Analyst-Ratings-1024x683.png","type":"image\/png"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"Latest US Analyst Ratings: March 12th, 2026","datePublished":"2026-03-13T05:04:37+00:00","dateModified":"2026-03-13T05:04:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/"},"wordCount":2778,"commentCount":938,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News & Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/","name":"Latest US Analyst Ratings: March 12th, 2026 | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2026-03-13T05:04:37+00:00","dateModified":"2026-03-13T05:04:37+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/latest-us-analyst-ratings-march-12th-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Latest US Analyst Ratings: March 12th, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/72584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=72584"}],"version-history":[{"count":6,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/72584\/revisions"}],"predecessor-version":[{"id":72591,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/72584\/revisions\/72591"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/71566"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=72584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=72584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=72584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}